CN Patent

CN112969459B — 用于口服给药的依达拉奉混悬剂

Assigned to Tanabe Pharma Corp · Expires 2023-12-05 · 2y expired

What this patent protects

本申请提供具有优异的生物利用度的用于口服给药的依达拉奉混悬剂。预期由此可减轻ALS患者和照料者的负担。

USPTO Abstract

本申请提供具有优异的生物利用度的用于口服给药的依达拉奉混悬剂。预期由此可减轻ALS患者和照料者的负担。

Drugs covered by this patent

Patent Metadata

Patent number
CN112969459B
Jurisdiction
CN
Classification
—
Expires
2023-12-05
Drug substance claim
No
Drug product claim
No
Assignee
Tanabe Pharma Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.